Literature DB >> 6287024

Mapping and identification of the vaccinia virus thymidine kinase gene.

D E Hruby, L A Ball.   

Abstract

The thymidine kinase gene of vaccinia virus (VV) was mapped on the viral genome by using cloned fragments of the viral DNA to hybridize to early viral mRNA. Individual DNA fragments that represented about half of the viral genome were assayed, both for their ability to arrest the cell-free synthesis of active VV thymidine kinase and for their ability to select functional mRNA for the viral enzyme. Both activities were located in HindIII fragment J, which maps near the middle of VV DNA and contains about 2.6% of the genome (4,800 base pairs). This DNA fragment encodes four known early polypeptides, and to determine which of these was thymidine kinase, early VV mRNA was fractionated by sucrose gradient centrifugation and used to direct cell-free synthesis of the active enzyme. The thymidine kinase mRNA cosedimented with several species that encoded polypeptides in the molecular weight range 15,000 to 25,000. Hybridization of these mRNAs to HindIII-J DNA selected a message that directed the synthesis of thymidine kinase and a single polypeptide with an apparent molecular weight of 19,000. The native molecular weight of VV thymidine kinase is about 80,000, so these data indicate that, unlike thymidine kinase from several other sources, the active VV enzyme is probably a tetramer of 19,000-molecular-weight subunits.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6287024      PMCID: PMC256142     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Deoxypyrimidine kinases of herpes simplex viruses types 1 and 2: comparison of serological and structural properties.

Authors:  M E Thouless; P Wildy
Journal:  J Gen Virol       Date:  1975-02       Impact factor: 3.891

2.  Molecular complexity of vaccinia DNA and the presence of reiterated sequences in the genome.

Authors:  L J Grady; E Paoletti
Journal:  Virology       Date:  1977-06-15       Impact factor: 3.616

3.  Purification of vaccinia virus-induced thymidine kinase activity from [35S]methionine-labeled cells.

Authors:  S Kit; G N Jorgensen; A Liav; V Zaslavsky
Journal:  Virology       Date:  1977-04       Impact factor: 3.616

4.  Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation.

Authors:  B M Paterson; B E Roberts; E L Kuff
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

5.  Herpes simplex virus-specific polypeptides studied by polyacrylamide gel electrophoresis of immune precipitates.

Authors:  R W Honess; D H Watson
Journal:  J Gen Virol       Date:  1974-02       Impact factor: 3.891

6.  Characterization and localization of the naturally occurring cross-links in vaccinia virus DNA.

Authors:  P Geshelin; K I Berns
Journal:  J Mol Biol       Date:  1974-10-05       Impact factor: 5.469

7.  Analysis of bacteriophage T7 early RNAs and proteins on slab gels.

Authors:  F W Studier
Journal:  J Mol Biol       Date:  1973-09-15       Impact factor: 5.469

8.  Vaccinia virus polypeptide synthesis: sequential appearance and stability of pre- and post-replicative polypeptides.

Authors:  T H Pennington
Journal:  J Gen Virol       Date:  1974-12       Impact factor: 3.891

9.  Studies on "early" enzymes in HeLa cells infected with vaccinia virus.

Authors:  C Jungwirth; W K Joklik
Journal:  Virology       Date:  1965-09       Impact factor: 3.616

10.  Vaccinia virus transcription: hybridization of mRNA to restriction fragments of vaccinia DNA.

Authors:  C V Cabrera; M Esteban; R McCarron; W T McAllister; J A Holowczak
Journal:  Virology       Date:  1978-05-01       Impact factor: 3.616

View more
  37 in total

1.  Transcriptional mapping and nucleotide sequence of a vaccinia virus gene encoding a polypeptide with extensive homology to DNA ligases.

Authors:  G L Smith; Y S Chan; S M Kerr
Journal:  Nucleic Acids Res       Date:  1989-11-25       Impact factor: 16.971

2.  In vitro resolution of poxvirus replicative intermediates into linear minichromosomes with hairpin termini by a virally induced Holliday junction endonuclease.

Authors:  D Stuart; K Ellison; K Graham; G McFadden
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

3.  Molecular genetic analysis of a vaccinia virus gene with an essential role in DNA replication.

Authors:  E Evans; P Traktman
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

4.  Transcriptional and translational mapping and nucleotide sequence analysis of a vaccinia virus gene encoding the precursor of the major core polypeptide 4b.

Authors:  J Rosel; B Moss
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

5.  Streptococcus gordonii strains resistant to fluorodeoxyuridine contain mutations in the thymidine kinase gene and are deficient in thymidine kinase activity.

Authors:  C A Franke; T M Bolman; S A Ottum; K F Jones; D E Hruby
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

6.  Vaccinia virus encodes a thymidylate kinase gene: sequence and transcriptional mapping.

Authors:  G L Smith; A de Carlos; Y S Chan
Journal:  Nucleic Acids Res       Date:  1989-10-11       Impact factor: 16.971

7.  Vaccinia virus induces ribonucleotide reductase in primate cells.

Authors:  M B Slabaugh; T L Johnson; C K Mathews
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

8.  Vaccinia virus-induced ribonucleotide reductase can be distinguished from host cell activity.

Authors:  M B Slabaugh; C K Mathews
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

9.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

10.  Mapping of the vaccinia virus DNA polymerase gene by marker rescue and cell-free translation of selected RNA.

Authors:  E V Jones; B Moss
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.